

REFERENCE

1. Freeman, A. F., & Holland, S. M. (2008). The hyper-IgE syndromes. *Immunology and allergy clinics of North America*, 28(2), 277–viii. <https://doi.org/10.1016/j.iac.2008.01.005>
2. Grimbacher, B., Holland, S. M., & Puck, J. M. (2005). Hyper-IgE syndromes. *Immunological reviews*, 203, 244–250. <https://doi.org/10.1111/j.0105-2896.2005.00228.x>
3. Renner, E. D., Puck, J. M., Holland, S. M., Schmitt, M., Weiss, M., Frosch, M., Bergmann, M., Davis, J., Belohradsky, B. H., & Grimbacher, B. (2004). Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. *The Journal of pediatrics*, 144(1), 93–99. [https://doi.org/10.1016/S0022-3476\(03\)00449-9](https://doi.org/10.1016/S0022-3476(03)00449-9)
4. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. (2007). STAT3 mutations in the hyper-IgE syndrome. *The New England journal of medicine*, 357(16), 1608–1619. <https://doi.org/10.1056/NEJMoa073687>
5. Grimbacher B, Schäffer AA, Holland SM, Davis J, Gallin JI, Malech HL, et al. (1999). Genetic linkage of hyper-IgE syndrome to chromosome 4. *American journal of human genetics*, 65(3), 735–744. <https://doi.org/10.1086/302547>
6. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. (2007). Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. *Nature*, 448(7157), 1058–1062. <https://doi.org/10.1038/nature06096>
7. Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. (2009). Combined immunodeficiency associated with DOCK8 mutations. *The New England journal of medicine*, 361(21), 2046–2055. <https://doi.org/10.1056/NEJMoa0905506>
8. Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, et al. (2009). Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. *The Journal of allergy and clinical immunology*, 124(6), 1289–302.e4. <https://doi.org/10.1016/j.jaci.2009.10.038>
9. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. (2011). Global study of primary immunodeficiency diseases (PI)--diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. *Immunologic research*, 51(1), 61–70. <https://doi.org/10.1007/s12026-011-8241-y>
10. Zhang, Q., & Su, H. C. (2011). Hyperimmunoglobulin E syndromes in pediatrics. *Current opinion in pediatrics*, 23(6), 653–658. <https://doi.org/10.1097/MOP.0b013e32834c7f65>
11. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. (2012). Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. *Medicine*, 91(4), e1–e19. <https://doi.org/10.1097/MD.0b013e31825f95b9>
12. Freeman, A. F., Kleiner, D. E., Nadiminti, H., Davis, J., Quezado, M., Anderson, V., Puck, J. M., & Holland, S. M. (2007). Causes of death in hyper-IgE syndrome. *The Journal of allergy and clinical immunology*, 119(5), 1234–1240. <https://doi.org/10.1016/j.jaci.2006.12.666>
13. Freeman, A. F., & Holland, S. M. (2009). Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. *Pediatric research*, 65(5 Pt 2), 32R–37R. <https://doi.org/10.1203/PDR.0b013e31819dc8c5>



14. Ibrahim, M. K., Zambruni, M., Melby, C. L., & Melby, P. C. (2017). Impact of Childhood Malnutrition on Host Defense and Infection. *Clinical microbiology reviews*, 30(4), 919–971. <https://doi.org/10.1128/CMR.00119-16>
15. Gernez Y, Freeman AF, Holland SM, Garabedian EN. (2018). Autosomal Dominant Hyper-IgE Syndrome in the USIDNET Registry. *The journal of allergy and clinical immunology. In practice*, 6(3), 996–1001. <https://doi.org/10.1016/j.jaip.2017.06.041>